CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cullinan Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$13.98+1.05 (+8.12%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
72M of 64M shares
Institutional holders
184
32 new, 20 sold out
Net institutional buying
6M
In Q2 2026
Insider trades, 12 months
1 buys · 28 sales
Net sold $1.12M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Weston Nichols | 8,549,084 | 14.50% | 13G (passive) amendment | Oct 8, 2025 |
| Bvf Partners L P/Il | 6,491,123 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Bvf Inc/Il | 6,161,469 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Lampert Mark N | 5,918,481 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
| Lynx1 Capital Management LP | 5,766,090 | 9.80% | 13G (passive) amendment | Sep 30, 2025 |
| BlackRock, Inc. | 4,338,725 | 7.50% | 13G (passive) | Sep 30, 2024 |
| T. Rowe Price Associates, Inc. | 3,825,950 | 6.20% | 13G (passive) | Jun 30, 2026 |
| State Street Corporation | 3,668,627 | 6.00% | 13G (passive) | Jun 30, 2026 |
| Kynam Capital Management, LP | 3,114,132 | 5.27% | 13G (passive) | Dec 31, 2025 |
| Morana Jovan-Embiricos | 2,177,461 | 5.09% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CGEM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Mpm Bioimpact LLC | 9,731,341 | 15.12% | $177.21M | +2,083,073 | 10.81% |
| Lynx1 Capital Management LP | 8,963,500 | 13.93% | $163.23M | – | 18.86% |
| Bvf Inc/Il | 5,750,683 | 8.94% | $104.72M | – | 2.68% |
| BlackRock, Inc. | 5,232,766 | 8.13% | $95.29M | +782,800 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 3,825,950 | 5.95% | $69.67K | +1,796,231 | 0.01% |
| State Street Corp | 3,668,627 | 5.70% | $66.81M | +1,124,512 | 0.00% |
| Kynam Capital Management, LP | 3,114,132 | 4.84% | $56.71M | – | 3.13% |
| Vanguard Capital Management LLC | 2,614,066 | 4.06% | $47.60M | +131,032 | 0.00% |
| Rtw Investments, LP | 2,364,347 | 3.67% | $43.05M | +658,387 | 0.37% |
| Siren, L.L.C. | 1,893,410 | 2.94% | $34.48M | +700,000 | 0.70% |
| Geode Capital Management, LLC | 1,547,309 | 2.40% | $28.18M | +179,041 | 0.00% |
| Blue Owl Capital Holdings LP | 1,539,764 | 2.39% | $28.04M | −370,000 | 4.22% |
| VR Adviser, LLC | 1,379,965 | 2.14% | $25.13M | – | 0.76% |
| Boothbay Fund Management, LLC | 1,082,611 | 1.68% | $19.71M | −30,192 | 0.26% |
| Dimensional Fund Advisors LP | 1,046,694 | 1.63% | $19.06M | +140,666 | 0.00% |
| Goldman Sachs Group Inc | 1,001,598 | 1.56% | $18.24M | +546,149 | 0.00% |
| Affinity Asset Advisors, LLC | 875,760 | 1.36% | $15.95M | +94,500 | 0.72% |
| Vanguard Portfolio Management LLC | 738,741 | 1.15% | $13.45M | +186,188 | 0.00% |
| Boone Capital Management LLC | 704,442 | 1.09% | $12.83M | New | 3.00% |
| Elmind Capital, LP | 690,000 | 1.07% | $12.56M | +160,000 | 3.16% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 184 | 72M | 100.0% | 32 / 84 | 47 / 20 | 12M | 6M |
| Q1 2026 | 174 | 66M | 100.0% | 40 / 61 | 42 / 17 | 11M | 5M |
| Q4 2025 | 153 | 63M | 98.2% | 29 / 66 | 41 / 18 | 13M | 11M |
| Q3 2025 | 145 | 61M | 95.0% | 28 / 56 | 37 / 26 | 5M | 6M |
| Q2 2025 | 143 | 63M | 97.3% | 20 / 51 | 45 / 24 | 3M | 5M |
| Q1 2025 | 148 | 65M | 100.0% | 27 / 45 | 50 / 23 | 7M | 7M |
| Q4 2024 | 146 | 66M | 100.0% | 30 / 54 | 36 / 20 | 8M | 8M |
| Q3 2024 | 137 | 65M | 100.0% | 20 / 66 | 28 / 17 | 13M | 7M |
| Q2 2024 | 135 | 63M | 97.8% | 39 / 60 | 26 / 16 | 28M | 7M |
| Q1 2024 | 113 | 42M | 64.8% | 19 / 41 | 37 / 18 | 8M | 4M |
| Q4 2023 | 113 | 38M | 58.8% | 23 / 45 | 25 / 14 | 8M | 5M |
| Q3 2023 | 106 | 38M | 59.5% | 13 / 35 | 31 / 13 | 3M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CGEM | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,377,645 | 3.69% | $43.30M | 0.40% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,929,766 | 3.00% | $35.14M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,577,982 | 2.45% | $28.74M | 0.03% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,019,356 | 1.58% | $18.56M | 0.13% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 660,987 | 1.03% | $10.91M | 0.03% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 621,218 | 0.97% | $11.31M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 583,803 | 0.91% | $10.63M | 0.09% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 562,565 | 0.87% | $10.24M | 0.07% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 559,800 | 0.87% | $10.19M | 0.10% | Jun 30, 2026 |
| iShares Biotechnology ETF | 318,933 | 0.50% | $5.81M | 0.06% | Jun 30, 2026 |
| Vanguard Explorer Fund | 303,486 | 0.47% | $5.01M | 0.02% | Jul 31, 2026 |
| Nuveen Quant Small Cap Equity Fund | 301,774 | 0.47% | $4.98M | 0.12% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 277,141 | 0.43% | $4.56M | 0.03% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 266,914 | 0.41% | $4.39M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 246,130 | 0.38% | $4.05M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Nadim Ahmed | President and CEO, Director | 390,803 | 0.61% | Feb 25, 2026 |
| Jennifer Michaelson | Chief Scientific Officer | 166,844 | 0.26% | Sep 10, 2026 |
| Jacquelyn L. Sumer | Chief Legal Officer | 130,559 | 0.20% | Jul 2, 2026 |
| Mary Kay Fenton | Chief Financial Officer | 127,921 | 0.20% | Jul 2, 2026 |
| Jeffrey Alan Jones | Chief Medical Officer | 159,968 | 0.25% | Feb 25, 2026 |
| Corrine Savill | Chief Business Officer | 240,990 | 0.37% | Feb 19, 2026 |
| Andrew R. Allen | Director | – | – | Jun 18, 2026 |
| Mary Thistle | Director | – | – | Jun 18, 2026 |
| Stephen W. Webster | Director | – | – | Jun 18, 2026 |
| David D. Meek | Director | – | – | Jun 18, 2026 |
| Anthony Rosenberg | Director | 45,002 | 0.07% | Jun 18, 2026 |
| Mittie Doyle | Director | – | – | Jun 18, 2026 |
| Anne-Marie Martin | Director | – | – | Jun 16, 2025 |
| David P. Ryan | Director | – | – | Jun 16, 2025 |
| Capital Management LP Lynx1 | 10% owner | 8,797,833 | 13.67% | Oct 30, 2025 |
| Weston Nichols | 10% owner | 8,963,500 | 13.93% | Oct 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jennifer Michaelson Chief Scientific Officer | Sep 8, 2026 | Option exercise | +4,000 | $4.30 | $17.20K | 166,844 |
| Jennifer Michaelson Chief Scientific Officer | Sep 8, 2026 | Sale(10b5-1 plan) | −8,000 | $21.57 | $172.56K | 158,844 |
| Jennifer Michaelson Chief Scientific Officer | Aug 13, 2026 | Sale(10b5-1 plan) | −30,000 | $20.26 | $607.80K | 162,844 |
| Jennifer Michaelson Chief Scientific Officer | Aug 13, 2026 | Option exercise | +30,000 | $4.30 | $129.00K | 192,844 |
| Jennifer Michaelson Chief Scientific Officer | Jul 6, 2026 | Option exercise | +4,000 | $4.30 | $17.20K | 170,844 |
| Jennifer Michaelson Chief Scientific Officer | Jul 6, 2026 | Sale(10b5-1 plan) | −8,000 | $17.82 | $142.56K | 162,844 |
| Jacquelyn L. Sumer Chief Legal Officer | Jun 30, 2026 | Award | +2,470 | $8.60 | $21.24K | 130,559 |
| Mary Kay Fenton Chief Financial Officer | Jun 30, 2026 | Award | +1,541 | $8.60 | $13.25K | 127,921 |
| Jennifer Michaelson Chief Scientific Officer | May 5, 2026 | Option exercise | +4,000 | $4.30 | $17.20K | 174,844 |
| Jennifer Michaelson Chief Scientific Officer | May 5, 2026 | Sale(10b5-1 plan) | −7,800 | $14.60 | $113.88K | 167,044 |
| Jennifer Michaelson Chief Scientific Officer | May 5, 2026 | Sale(10b5-1 plan) | −200 | $15.58 | $3.12K | 166,844 |
| Jennifer Michaelson Chief Scientific Officer | Mar 5, 2026 | Sale(10b5-1 plan) | −8,000 | $15.68 | $125.44K | 170,844 |
| Jennifer Michaelson Chief Scientific Officer | Mar 5, 2026 | Option exercise | +4,000 | $4.30 | $17.20K | 178,844 |
| Jennifer Michaelson Chief Scientific Officer | Feb 25, 2026 | Sale(10b5-1 plan) | −1,780 | $14.14 | $25.17K | 174,844 |
| Jennifer Michaelson Chief Scientific Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −3,601 | $14.47 | $52.11K | 176,624 |
| Nadim Ahmed President and CEO, Director | Feb 24, 2026 | Sale | −13,515 | $14.47 | $195.56K | 390,803 |
| Jacquelyn L. Sumer Chief Legal Officer | Feb 24, 2026 | Sale | −3,601 | $14.47 | $52.11K | 128,089 |
| Jeffrey Alan Jones Chief Medical Officer | Feb 24, 2026 | Sale | −4,582 | $14.47 | $66.30K | 159,968 |
| Jennifer Michaelson Chief Scientific Officer | Feb 23, 2026 | Sale(10b5-1 plan) | −1,752 | $13.99 | $24.51K | 180,225 |
| Nadim Ahmed President and CEO, Director | Feb 20, 2026 | Sale | −16,381 | $13.62 | $223.11K | 404,318 |
| Jennifer Michaelson Chief Scientific Officer | Feb 20, 2026 | Sale(10b5-1 plan) | −3,742 | $13.62 | $50.97K | 181,977 |
| Jennifer Michaelson Chief Scientific Officer | Feb 20, 2026 | Option exercise | +8,000 | $4.30 | $34.40K | 189,977 |
| Jennifer Michaelson Chief Scientific Officer | Feb 20, 2026 | Sale(10b5-1 plan) | −8,000 | $14.30 | $114.40K | 181,977 |
| Jacquelyn L. Sumer Chief Legal Officer | Feb 20, 2026 | Sale | −3,742 | $13.62 | $50.97K | 131,690 |
| Mary Kay Fenton Chief Financial Officer | Feb 20, 2026 | Sale | −4,398 | $13.62 | $59.90K | 126,380 |
| Jeffrey Alan Jones Chief Medical Officer | Feb 20, 2026 | Sale | −4,982 | $13.62 | $67.85K | 164,550 |
| Mary Kay Fenton Chief Financial Officer | Feb 18, 2026 | Award | +68,750 | – | – | 130,778 |
| Jennifer Michaelson Chief Scientific Officer | Feb 18, 2026 | Award | +57,500 | – | – | 185,719 |
| Jennifer Michaelson Chief Scientific Officer | Feb 12, 2026 | Sale | −416 | $12.03 | $5.00K | 128,219 |
| Jennifer Michaelson Chief Scientific Officer | Jan 22, 2026 | Sale(10b5-1 plan) | −4,000 | $12.30 | $49.20K | 128,635 |
| Mary Kay Fenton Chief Financial Officer | Dec 31, 2025 | Award | +27 | $6.49 | $175 | 62,028 |
| Nadim Ahmed President and CEO, Director | Dec 23, 2025 | Sale | −9,922 | $10.01 | $99.32K | 420,699 |
| Jennifer Michaelson Chief Scientific Officer | Dec 19, 2025 | Sale(10b5-1 plan) | −1,345 | $10.01 | $13.46K | 132,635 |
| Jacquelyn L. Sumer Chief Legal Officer | Dec 18, 2025 | Sale | −3,480 | $9.67 | $33.65K | 135,432 |
| Jeffrey Alan Jones Chief Medical Officer | Dec 18, 2025 | Sale | −4,632 | $9.67 | $44.79K | 169,532 |
| Jennifer Michaelson Chief Scientific Officer | Dec 18, 2025 | Sale | −2,898 | $9.67 | $28.02K | 133,980 |
| Jennifer Michaelson Chief Scientific Officer | Dec 15, 2025 | Sale(10b5-1 plan) | −995 | $11.90 | $11.84K | 136,878 |
| Jennifer Michaelson Chief Scientific Officer | Dec 12, 2025 | Sale(10b5-1 plan) | −2,148 | $12.38 | $26.59K | 137,873 |
| Jennifer Michaelson Chief Scientific Officer | Nov 24, 2025 | Sale(10b5-1 plan) | −4,000 | $12.30 | $49.20K | 138,004 |
| Weston Nichols 10% owner | Oct 28, 2025 | Buy | +165,667 | $8.40 | $1.39M | 8,963,500 |
| Capital Management LP Lynx1 10% owner | Oct 17, 2025 | Buy | +32,217 | $7.84 | $252.58K | 8,797,833 |
| Capital Management LP Lynx1 10% owner | Oct 16, 2025 | Buy | +150,000 | $8.86 | $1.33M | 8,765,616 |
| Capital Management LP Lynx1 10% owner | Oct 15, 2025 | Buy | +51,500 | $7.94 | $408.91K | 8,615,616 |
| Capital Management LP Lynx1 10% owner | Oct 14, 2025 | Buy | +15,032 | $7.59 | $114.09K | 8,564,116 |
| Capital Management LP Lynx1 10% owner | Oct 10, 2025 | Buy | +277,298 | $7.36 | $2.04M | 8,549,084 |
| Capital Management LP Lynx1 10% owner | Oct 9, 2025 | Buy | +626,043 | $6.70 | $4.19M | 8,271,786 |
| Capital Management LP Lynx1 10% owner | Oct 8, 2025 | Buy | +556,300 | $6.46 | $3.59M | 7,645,743 |
| Nadim Ahmed President and CEO, Director | Feb 25, 2025 | Sale | −12,529 | $8.53 | $106.87K | 430,621 |
| Jeffrey Alan Jones Chief Medical Officer | Feb 25, 2025 | Sale | −4,895 | $8.53 | $41.75K | 174,164 |
| Jennifer Michaelson Chief Scientific Officer | Feb 25, 2025 | Sale | −3,756 | $8.53 | $32.04K | 142,004 |
| Jacquelyn L. Sumer Chief Legal Officer | Feb 25, 2025 | Sale | −3,756 | $8.53 | $32.04K | 136,895 |
| Jeffrey Alan Jones Chief Medical Officer | Feb 19, 2025 | Award | +65,000 | – | – | 179,059 |
| Nadim Ahmed President and CEO, Director | Feb 19, 2025 | Award | +180,000 | – | – | 443,150 |
| Corrine Savill Chief Business Officer | Feb 19, 2025 | Award | +37,500 | – | – | 240,990 |
| Mary Kay Fenton Chief Financial Officer | Feb 19, 2025 | Award | +60,000 | – | – | 60,000 |
| Jennifer Michaelson Chief Scientific Officer | Feb 19, 2025 | Award | +50,000 | – | – | 145,760 |
| Jacquelyn L. Sumer Chief Legal Officer | Feb 19, 2025 | Award | +50,000 | – | – | 140,651 |
| Jennifer Michaelson Chief Scientific Officer | Jan 6, 2025 | Sale(10b5-1 plan) | −4,000 | $12.51 | $50.04K | 95,760 |
| Nadim Ahmed President and CEO, Director | Dec 24, 2024 | Sale | −8,400 | $11.87 | $99.71K | 263,150 |
| Jacquelyn L. Sumer Chief Legal Officer | Dec 18, 2024 | Sale | −3,482 | $11.41 | $39.73K | 90,651 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Michaelson Jennifer Officer | Sep 8, 2026 | 8,000 | $176.72K | Sep 8, 2026 | Exercise of Stock Options |
| Michaelson Jennifer Officer | Aug 13, 2026 | 30,000 | $588.00K | Aug 13, 2026 | Exercise of Stock Options |
| Michaelson Jennifer Officer | Jul 6, 2026 | 8,000 | $141.04K | Jul 6, 2026 | Exercise of Stock Options |
| Michaelson Jennifer Officer | May 5, 2026 | 8,000 | $122.72K | May 5, 2026 | Exercise of Stock Options |
| Michaelson Jennifer Officer | Mar 5, 2026 | 8,000 | $130.40K | Mar 5, 2026 | Exercise of Stock Options |
| Michaelson Jennifer Officer | Feb 25, 2026 | 1,780 | $25.40K | Feb 25, 2026 | Restricted Stock Units |
| Michaelson Jennifer Officer | Feb 23, 2026 | 1,752 | $23.91K | Feb 23, 2026 | Restricted Stock Units |
| Michaelson Jennifer Officer | Feb 20, 2026 | 8,000 | $111.04K | Feb 20, 2026 | Exercise of Stock Options |
| Michaelson Jennifer Officer | Jan 22, 2026 | 4,000 | $46.40K | Jan 22, 2026 | Restricted Stock Units |
| Michaelson Jennifer Officer | Dec 19, 2025 | 1,345 | $13.42K | Dec 19, 2025 | Restricted Stock Units |
| Michaelson Jennifer Officer | Dec 15, 2025 | 995 | $11.86K | Dec 15, 2025 | Restricted Stock Units |
| Michaelson Jennifer Officer | Nov 24, 2025 | 4,000 | $37.88K | Nov 24, 2025 | Restricted Stock Units |
| Michaelson Jennifer Officer | Jan 6, 2025 | 8,000 | $101.44K | Jan 6, 2025 | Restricted Stock Units |
| Michaelson & Marc D. Michaelson Jennifer Officer | Sep 5, 2024 | 16,000 | $298.88K | Sep 5, 2024 | Restricted Stock Awards |
| Michaelson & Marc D. Michaelson Jennifer Officer | Jul 5, 2024 | 5,606 | $94.07K | Jul 5, 2024 | RSA & RSU |